Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/147097
Title: | PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness |
Author: | Molleví, David G. Aytés Meneses, Álvaro Padullés Mosella, Laura Martínez Iniesta, María Baixeras, Núria Salazar Soler, Ramón Ramos Rubio, Emilio Figueras Aloy, José, 1950- Capellá, G. (Gabriel) Villanueva Garatachea, Alberto |
Keywords: | Metabolisme Càncer colorectal Patologia Càncer de fetge Metabolism Colorectal cancer Pathology Liver cancer |
Issue Date: | 28-Oct-2008 |
Publisher: | Cancer Research UK |
Abstract: | Phosphatase PRL-3 has been involved in different types of cancer, especially in metastases from colorectal carcinoma (CRC). In this study, we explored both isoforms of PRL-3 as a biomarker to predict the recurrence of stage IIIB-C CRC. Overexpression of PRL-3 was investigated in primary human colorectal tumours (n=20) and hepatic metastases (n=36) xenografted in nude mice, samples characterised by absence of human non-tumoral cells, showing a high degree of expression in metastases (P=0.001). In 27 cases of matched normal colonic mucosa/primary tumour/hepatic metastases, PRL-3 overexpression occurs in primary tumours vs normal mucosa (P=0.001) and in hepatic metastases vs primary tumours (P=0.045). Besides, our results in a series of 80 stage IIIB-C CRC primary tumours showed that high levels of PRL-3 were an independent predictor of metastasis (P<0.0001; OR: 9.791) in multivariate analysis of a binary logistic regression and that PRL-3 expression tightly correlates with parameters of bad outcome. Moreover, PRL-3 expression associated with poor outcome in univariate (P<0.0001) and multivariate Cox models (hazard ratio: 3.322, 95%, confidence interval: 1.405-7.852, P=0.006). In conclusion, PRL-3 is a good marker of aggressiveness of locally advanced CRS and a promising predictor of distant metastases. Nevertheless, for prognosis purposes, it is imperative to validate the cutoff value of PRL-3 expression in a larger and consecutive series and adjuvant setting. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1038/sj.bjc.6604747 |
It is part of: | British Journal of Cancer, 2008, vol. 99, num. 10, p. 1718-1725 |
URI: | http://hdl.handle.net/2445/147097 |
Related resource: | https://doi.org/10.1038/sj.bjc.6604747 |
ISSN: | 0007-0920 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
606220.pdf | 310.09 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.